encompasses four products. Our lead product (IMK-101) is an off-the-shelf, non-genome edited CD7 CAR-iNKT cell therapy with the potential to treat T-cell leukemia, lymphoma, and AML. The other two products include an unmodified native type III NKT cell therapy (IMK-102) targeting AML and a CAR-iNKT cell therapy (IMK-103) targeting solid tumors. We also intend to explore the potential of these assets in the arena of autoimmune diseases in the future.